Alefacept (Amevive) for treatment of psoriasis.
D000077944:Alefacept; D023341:Chills / Q000139:chemically induced; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005252:Fees, Pharmaceutical; D006801:Humans; D007156:Immunologic Memory / Q000187:drug effects; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008213:Lymphocyte Activation / Q000187:drug effects; D015337:Multicenter Studies as Topic; D011565:Psoriasis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013601:T-Lymphocytes / Q000276:immunology
D011993:Recombinant Fusion Proteins; D000077944:Alefacept